
    
      Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c
      Melanoma that may not meet the eligibility criteria to enroll in another ongoing Talimogene
      Laherparepvec study or do not have access to enroll in an ongoing Talimogene Laherparepvec
      study.
    
  